«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

20卷

期数:

2014年01期

页码:

21-024

栏目:

临床医学

出版日期:

2014-01-20

文章信息/Info

Title:

Comparative study of using biodegradable polymer drug eluting stents and durable polymer drug eluting stents in the treatment of coronary artery disease

文章编号:

1006-8147(2014)01-0021-04

作者:

李时乐¹ ; 徐延敏²

( 天津医科大学第二医院心脏科,天津 300211)

Author(s):

LI Shi-le¹ ; XU Yan-min²

(Department of Cardiology, The Second Hospital,Tianjin Medical University, Tianjin 300211, China)

关键词:

冠状动脉疾病; 药物洗脱支架; 涂层可降解; 对比研究

Keywords:

coronary artery disease;  drug eluting stent;  biodegradable polymer coating;  comparative study

分类号:

R541.4

DOI:

-

文献标志码:

A

摘要:

目的: 比较涂层可降解药物洗脱支架（Excel）与涂层不可降解药物洗脱支架（Partner）在冠状动脉疾病治疗中的近期疗效及安全性。方法：将1 315例接受药物洗脱支架治疗的冠心病患者纳入此回顾性对照研究，其中Excel组498例，Partner组817例.观察术后1年内两组患者主要不良心脏事件（MACE）及支架内血栓事件发生情况。结果：两组患者在基线资料、冠脉病变特征等方面均无统计学差异（P>0.05）；两组患者平均置入支架直径﹝（2.97±0.39）mm vs（3.03±0.46）mm﹞及置入支架长度﹝（25.37±7.39）mm vs（24.57±7.11）mm﹞比较，差异均有统计学意义（P<0.05）.尽管Excel组患者平均置入支架直径较小且支架长度偏长，但随访结果显示两组患者1年内主要不良心脏事件及支架内血栓事件发生情况差异均无统计学意义（2.41%vs2.69%，P>0.05；0.60%vs0.86%，P>0.05）。结论：涂层可降解与不可降解药物洗脱支架在冠状动脉疾病治疗中的近期疗效及安全性相似。

Abstract:

Objective: To compare the short-term effect and safety of using biodegradable polymer drug eluting stents(Excel) and durable polymer drug eluting stents(Partner) in the treatment of coronary artery disease. Methods: A cohort of 1315 consecutive patients with coronary arterial disease who underwent drug eluting stents implantation was carried out .The patients were divided into Excel group (n=498) and Partner group (n=817). The incidence of main adverse cardiac event（MACE）and stent thrombosis(ST) were followed up within one year. Results: Two groups were similar in main baseline clinical information and major angiography characteristics. While the stents of the Excel group had a smaller diameter﹝（2.97±0.39）mm vs（3.03±0.46）mm﹞ and a longer length﹝（25.37±7.39）mm vs（24.57±7.11）mm﹞ than the those of Partner group on average, the difference was statistically significant. During the period of follow-up, the incidence of MACE was 2.41% in Excel group and 2.69% in Partner group, with no significant difference (P>0.05); andthe incidence of stent thrombosis was 0.60% in Excel group whereas 0.86% in Partner group, indicating no significant difference (P>0.05). Conclusion: The short-term effect and safety of using biodegradable polymer drug eluting stents(Excel) and durable polymer drug eluting stents(Partner) in the treatment of coronary artery disease are similar.

参考文献/References:

[1] Byrne R A，Sarafoff N，Kastrati A，et al . Drug- eluting stents in percutaneous coronary intervention: a benefit- risk assessment [J] . Drug Saf，2009，32( 9) : 749
[2] Virmani R,Guagliumi G, Farb A, et al.Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent:Should we be cautious[J] .Circulation,2004,109(6):701
[3] Cutlip D E, Windecker S , Mehran R, et al. Clinical end point in coronary stent trials: a case for standardized definitions[J]. Circulation , 2007, 115( 17) : 2344
[4] Shafiq N, Malhotra S, Pandhi P, et al. A meta analysis of clinical trials of paclitaxel and sirolimus-eluting stents in patients with obstructive coronary artery disease[J]. Br J Clin Pharmacol , 2005, 59(1):94
[5] Slottow T L,Waksman R. Drug eluting stent safety [J]. Am J Cardiol, 2007, 100( 8B) :10M
[6]Cook S，Ladich E，Nakazawa G,et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis[J].Circulation， 2009，120(5):391
[7] Stefanini G G,Kalesan B,Serruys P W,et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease(LEADERS):4 year follow-up of a randomised non-inferiority trial [J].Lancet，2011，378(9807):1940
[8] Stefanini G G, Byrne R A, Serruys P W,et al.Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention:a pooled analysis of individual date from the ISAR-TEST3、ISAR-TEST4,and LEADERS randomized trials [J]. Eur Heart J，2012，33（10）:1214
[9] HAN Y L, ZHANG L, YANG L X,et al.A new generation of biodegradable polymer-coated sirolimus eluting stents for the treatment of coronary artery disease:final 5-year clinical outcomes from the CREATE study[J].EuroIntervention，2012 ，8(7):815
[10] Stone G W, Midei M, Newman W, et al.Comparison of an everolimus-eluting and a paclitaxel-eluting stent in patients with coronary artery disease[J]. JAMA, 2008, 299（16）: 1903
[11] 霍勇，李占全，何奔，等.国产Partner冠状动脉支架治疗冠心病的疗效及临床随访[J] . 中国介入心脏病学杂志, 2008, 16 (5) :243
[12]Navarese E P,Kubica J,Castriota F,et al. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials[J].EuroIntervention，2011，7（8）:985

相似文献/References:

[1]王树峰,杨 丽,刘 寅.脂蛋白相关磷脂酶A2与冠心病和2型糖尿病的关系[J].天津医科大学学报,2013,19(06):456.
　WANG Shu-feng,YANG Li,LIU Yin.Relationship between lipoprotein-associated phospholipase A2 and coronary heart disease as well as type 2 diabetes mellitus[J].Journal of Tianjin Medical University,2013,19(01):456.
[2]孙旭森,张宇凡,李沅洋,等.Apelin-13在冠状动脉粥样硬化病变临床诊断中的应用价值[J].天津医科大学学报,2019,25(06):572.
　SUN Xu-sen,ZHANG Yu-fan,LI Yuan-yang,et al.Application value of Apelin-13 in the clinical diagnosis of coronary arteriosclerosis[J].Journal of Tianjin Medical University,2019,25(01):572.

备注/Memo

备注/Memo:

作者简介 李时乐（1987-），男，硕士在读，研究方向：心血管病；
通信作者：徐延敏，E-mail： xuyanminphd@aliyun.com。

常用功能

更新日期/Last Update: 2014-03-27